Trials / Unknown
UnknownNCT04501029
A Study of Gimatecan (ST1481) in Small Cell Lung Cancer
A Phase Ib/II Study of Gimatecan (ST1481) for Small Cell Lung Cancer Patients Who Failed Standard Platinum-containing Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Lee's Pharmaceutical Limited · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This phase Ib/II clinical trial studies the safety and effect of Gimatecan in small cell lung cancer patients who failed the first-line standard platinum-containing chemotherapy. The chemotherapy will be given every four weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gimatecan | Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks. |
Timeline
- Start date
- 2020-10-01
- Primary completion
- 2022-10-01
- Completion
- 2023-10-01
- First posted
- 2020-08-06
- Last updated
- 2020-08-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04501029. Inclusion in this directory is not an endorsement.